Page last updated: 2024-10-26

famotidine and Methemoglobinemia

famotidine has been researched along with Methemoglobinemia in 1 studies

Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Methemoglobinemia: The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait). (Dorland, 27th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Malfará, WR1
Pereira, CP1
Santos, AC1
Queiroz, RH1

Other Studies

1 other study available for famotidine and Methemoglobinemia

ArticleYear
Effects of H(2)-receptor antagonists on dapsone-induced methaemoglobinaemia in rats.
    Pharmacological research, 2002, Volume: 45, Issue:4

    Topics: Animals; Biotransformation; Dapsone; Dose-Response Relationship, Drug; Drug Interactions; Famotidine

2002